EuroIntervention is pleased to share with you our free State-of-the-Art papers collection: high-level insights on general topics of interventional interest, written by top-class international experts, with many more to come. Do you have topics to suggest? https://t.co/T8YD94rviu
This study of patients with refractory angina, showed that the application of the coronary sinus Reducer was associated with significant clinical benefits and with objective improvements in VO2 kinetics and effort tolerance. #EIJBestOf https://t.co/XcJPD0rb2w
@DrBIqbal Your guide extension was obclusive in LAD and when you injected contrast medium it dissected coronary and push back guide caterer and it's hydrophilic guide extension. I think.
71 Y, NSTEMI
EF 34%
MB, DA and CX 90% heavy calcified. Diag and marg 100%
Crea 2,3 mg/dl
PCI Strategy
1 Impella
2 PCI on marginal and diagonal
3 PCI on MB-DA-Cx bifurcation
Warning:
- low dose mdc
- complex PCI havy calcified and tortuosity
@skat_ct#complexpci#cto#impella
Sham-controlled COSIRA II RCT evaluating the coronary sinus REDUCER in pts w/refractory angina due to untreatable CAD has begun. Pivotal FDA IDE trial for US approval if safe and effective. Currently class IIb in the EU guidelines based on the positive predicate COSIRA I trial.
Lad and circumflex with separated origin and double ostial calcified stenosis. Kissing stent (3 x 12) xience x 2 and kissing balloon 3,5 x 12 mm NC x 2.
88 told women, no surgical option.